Page last updated: 2024-10-26

brl 42810 and Central Nervous System Viral Diseases

brl 42810 has been researched along with Central Nervous System Viral Diseases in 1 studies

Central Nervous System Viral Diseases: Viral infections of the brain, spinal cord, meninges, or perimeningeal spaces.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Whitley, RJ	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants[NCT00942084]			Phase 1	32 participants (Actual)	Interventional	2011-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clearance (CL)

"Timeframe:~Version 1:0-5 min,2-4 hrs,6-8 hrs post doses 1 and 5-15; prior to doses 5-15 Version 2:0-15 min post doses 1 and 5-15; within 30 min prior to doses 2 and 5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose" (NCT00942084)
Timeframe: V1:0-5 min,2-4 hrs,6-8 hrs post Doses 1&5-15;prior to doses 5-15; V2:0-15 min post doses 1&5-15; within 30 min prior to doses 2&5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose

Intervention	L/h/kg (Median)
Acyclovir Study Design	0.278

Half-life (T1/2)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	h (Median)
Acyclovir Study Design	7.07

Maximum Steady State Concentration (Cmaxss)

(NCT00942084)
Timeframe: up to 3 dasy of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	11.1

Minimum Steady State Concentration (Cminss)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	4.15

Steady State Concentration at 50% of the Dosing Interval (C50ss)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	6.33

Volume of Distribution (V)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	L/kg (Median)
Acyclovir Study Design	3.34

Reviews

1 review available for brl 42810 and Central Nervous System Viral Diseases

Article	Year
Herpes simplex virus infection. Seminars in pediatric infectious diseases, 2002, Volume: 13, Issue:1 Topics: 2-Aminopurine; Acquired Immunodeficiency Syndrome; Acyclovir; Administration, Oral; Adult; Antiviral	2002